Best practice advice for asthma exacerbation prevention and management in primary care: an international expert consensus.

Autor: Skolnik N; Thomas Jefferson University, Philadelphia, PA, USA.; Jefferson Health, Philadelphia, PA, USA., Yawn BP; University of Minnesota, Minneapolis, MN, USA., Correia de Sousa J; University of Minho, Braga, Portugal., Vázquez MMM; University of the Basque Country, Leioa, Spain.; International Primary Care Respiratory Group (IPCRG), Scotland, UK., Barnard A; International Primary Care Respiratory Group (IPCRG), Scotland, UK.; Australian National University, Canberra, ACT, Australia., Wright WL; Wright & Associates Family Healthcare, Amherst, MA, USA.; Partners in Healthcare Education, PLLC, Amherst, MA, USA., Ulrich A; Primary Care Education Consortium, Winnsboro, SC, USA. aulrich@pceconsortium.org., Winders T; Global Allergy & Airways Patient Platform, Vienna, Austria., Brunton S; US Primary Care Respiratory Group, Winnsboro, SC, USA.
Jazyk: angličtina
Zdroj: NPJ primary care respiratory medicine [NPJ Prim Care Respir Med] 2024 Nov 17; Vol. 34 (1), pp. 39. Date of Electronic Publication: 2024 Nov 17.
DOI: 10.1038/s41533-024-00399-2
Abstrakt: Primary care clinicians play a key role in asthma and asthma exacerbation management worldwide because most patients with asthma are treated in primary care settings. The high burden of asthma exacerbations persists and important practice gaps remain, despite continual advances in asthma care. Lack of primary care-specific guidance, uncontrolled asthma, incomplete assessment of exacerbation and asthma control history, and reliance on systemic corticosteroids or short-acting beta 2 -agonist-only therapy are challenges clinicians face today with asthma care. Evidence supports the use of inhaled corticosteroids (ICS) + fast-acting bronchodilator treatments when used as needed in response to symptoms to improve asthma control and reduce rates of exacerbations, and the symptoms that occur leading up to an asthma exacerbation provide a window of opportunity to intervene with ICS. Incorporating patient perspectives and preferences when designing asthma regimens will help patients be more engaged in their therapy and may contribute to improved adherence and outcomes. This expert consensus contains 10 Best Practice Advice Points from a panel of primary care clinicians and a patient representative, formed in collaboration with the International Primary Care Respiratory Group (IPCRG), a clinically led charitable organization that works locally and globally in primary care to improve respiratory health. The panel met virtually and developed a series of best practice statements, which were drafted and subsequently voted on to obtain consensus. Primary care clinicians globally are encouraged to review and adapt these best practice advice points on preventing and managing asthma exacerbations to their local practice patterns to enhance asthma care within their practice.
Competing Interests: Competing interests N.S. reports the following competing interests: Advisory Boards and Consultant - AstraZeneca, Teva, Lilly, Boehringer Ingelheim, Sanofi, Sanofi Pasteur, GSK, Bayer, Genentech, Abbott, Idorsia, Novartis, Novo Nordisk, Astellas; Speaker - AstraZeneca, Boehringer Ingelheim, Lilly, GSK, Teva, Bayer, Heartland, Astellas; Research Support - AstraZeneca, GSK, Novo Nordisk, Novartis. B.P.Y. reports the following competing interests: consultant and member of advisory boards related to asthma for AstraZeneca, GlaxoSmithKline, TEVA, Novartis, and Moderna. J.C.S. reports the following competing interests: Chair of the Asthma Right Care Strategy Team: International Primary Care Respiratory Group; Receipt of grants/research support: AstraZeneca and GSK; Receipt of honoraria or consultation fees: AstraZeneca, GSK, Bial, Sanofi, Medinfar; Participation in a company sponsored speaker’s bureau: AstraZeneca, Sanofi. M.M. reports the following competing interests: advisory board honoraria, lecture honoraria and travel bursary from AstraZeneca, Chiesi, and Menarini. A.B. reports no relevant competing interests. W.L.W. reports the following competing interests: Consultant and speaker for AstraZeneca. A.U. reports no relevant competing interests. T.W. reports the following competing interests: consultant for unbranded disease awareness, education, advocacy & research for AstraZeneca, Chiesi, GSK, Novartis, and Sanofi Regeneron. S.B. reports the following competing interests: Speakers Bureau: Boehringer Ingelheim, AstraZeneca. Ethical approval This declaration is not applicable, as this work did not involve patient-level data.CME certificationReaders of this article may receive continuing medical education (CME) credit by completing the survey below, depending on their local regulating bodies. Survey link: https://www.pcrg-us.org/survey/post/asthmaconsensus.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: